Title:
Recurrence of infection and diversity of Helicobacter pylori strains in an adult population in Mexico treated with empirical standard triple therapy.

Authors:
Jaime Alberto Sánchez Cuén, Ana Bertha Irineo Cabrales, Nidia Maribel Leon Sicairos, Loranda Calderón Zamora, Luis Monroy Higuera, Vicente Adrian Canizalez Román

DOI: 10.17235/reed.2017.4994/2017
Link: PubMed (Epub ahead of print)

Please cite this article as:

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Recurrence of infection and diversity of Helicobacter pylori strains in an adult population in Mexico treated with empirical standard triple therapy.

Recurrence of Helicobacter pylori infection

Jaime Alberto Sánchez-Cuéñ¹,³, Ana Bertha Irineo-Cabrales¹,², Nidia Maribel León-Sicairos³, Calderón-Zamora Loranda³, Luis Monroy-Higuera³, Vicente Adrián Canizalez-Román³.

¹Department of Digestive Diseases. Hospital Regional del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Culiacán, Sinaloa.

²Department of Postgraduate Studies. School of Medicine. Universidad Autónoma de Sinaloa. Culiacán, Sinaloa. Mexico.


Correspondence: MC Jaime Alberto Sánchez-Cuéñ. Department of Digestive, Hospital Regional ISSSTE de Culiacán. Calzada, Heroico Colegio Militar 875 Sur, colonia 5 de Mayo, CP 80000, Culiacán, Sinaloa, México. Tel 016677593400 Ext. 272. Correo electrónico: sanchezcuen_jaime@hotmail.com

Key words: Recurrence, Helicobacter pylori, eradication

Abbreviations:

Helicobacter pylori (H. pylori)
Antigenic protein (cagA)

Vacuolating cytotoxin (vacA)

Gene induced through contact with the epithelium (iceA)

Polymerase Chain Reaction (PCR)

Disintegrations Per Minute (DPM)

Proton-pump inhibitors (PPIs)

Ethical considerations. The research does not violate the concepts of authorship, plagiarism or conflict of interests.

Abstract.

Background. After eradication treatment for Helicobacter pylori, infection could recur due to recrudescence or re-infection. The objective of this study was to determine the recurrence of Helicobacter pylori infection and identify virulent Helicobacter pylori strains one year after eradication with standard triple therapy.

Material and methods. A quasi-experimental study was performed that included a patient population with digestive diseases associated with Helicobacter pylori who had received standard triple therapy. Cultures and Polymerase Chain Reaction was performed on gastric biopsies for strain identification in all patients prior to eradication treatment and those with a positive carbon 14 breath test one year after eradication treatment. Statistical analysis was performed using the student T test and Fisher’s exact test, statistical significance was set at 0.05.

Results. 128 patients were studied, 51 (39.8%) were male and 77 (60.2%) were female with an average age of 54.8 years (DE 13.8). There was an annual recurrence of Helicobacter pylori infection in 12 (9.3%) patients. An annual re-
infection and recrudescence occurred in 9 (7 %) and 3 (2.3%) patients respectively. The recrudescence rate for cagA was 1/30 (3.3%) patients and 2/112 (1.8%) patients for vacA. The re-infection rate for cagA was 3/30 (10%) patients and 6/112 (5.3%) patients for vacA.

Conclusions. The recurrence of infection in this study was higher than that recorded in developed countries with a low prevalence of H. pylori and lower than that recorded in developing countries with a higher prevalence of H. pylori. The cagA or vacA s2/m2 strains were isolated after re-infection and recrudescence.

Key words: Recurrence, Helicobacter pylori, eradication

Introduction.

Helicobacter pylori (H. pylori) is a spiral-shaped Gram-negative bacteria that colonizes the human stomach and can produce a long-term infection of the gastric mucosa (1). H. pylori infection has been present in gastroduodenal diseases, such as gastric ulcers, duodenal ulcers and gastric cancer for thousands of years (2). The gastric mucosa is colonized by H. pylori in more than 50 % of the population (3). Recent studies have demonstrated a prevalence level of 70.1 and 84.7% of H.pylori infection in the wider population in Mexico (4). H. pylori is classified as a Group I carcinogen by the International Agency for Research on Cancer (IARC) and is considered a primary factor for the development of gastric cancer (5). A sequential model has been described for preneoplastic injuries (atrophic gastritis, intestinal metaplasia and dysplasia) that range from H. pylori infection to the development of gastric cancer (6). The principal genes considered as virulence factors in H. pylori are the antigenic protein (gen cagA), the vacuolating cytotoxin (gen vacA), the promoting gene for duodenal ulcer (dupA), the gene induced through contact with the epithelium (iceA), the sialic acid-binding adhesin (sabA) and the outer inflammatory protein (gen oipA) (7). H. pylori strains, the cagA gene and more recently the vacA and iceAse genes, have been associated with a higher
risk of gastric cancer (8, 9,10).

There is still some controversy with regard to eradication treatment for *H. pylori* in asymptomatic patients (11). However, there is evidence that shows that the incidence and prevalence of uncomplicated peptic ulcers and the incidence of gastric cancer have decreased during recent years. This is mainly due to the availability of treatments to eradicate *H. pylori* in symptomatic patients (12). However, after eradication treatment, *H. pylori* infection could recur due to recrudescence (re-colonization by the same strain) or re-infection (colonization by a new strain) (13). The annual recurrence rates of *H. pylori* infection can vary from country to country (14). The recurrence of *H. pylori* subsequent to eradication is rare in developed countries and more frequent in developing countries. Recrudescence is thought to cause recurrence within the first 12 months after the eradication of *H. pylori* and re-infection can occur during the same period. The annual rate of *H. pylori* recurrence is 2.67 % and 13 % in developed and developing countries, respectively (15). Treatment with a low efficacy antibiotic increases the probability of a recrudescence of the *H. pylori* infection (16). Acquired immunity probably varies little from one population to the next and re-infections mostly likely occur in areas with a high prevalence of *H. pylori* infection that ultimately increase the possibility of transmission (17). A recent study indicated that the average values obtained from the post-eradication breath tests for *H. pylori* infection are a predictive factor for recurrence. Variables such as gender, rural and urban location, smoking habits, the eradication regimen and the method for confirming eradication have never been considered as possible predictive variables (18). In populations with a high recurrence of *H. pylori* infection, eradication may not be effective in the long-term and may increase the prevalence of gastric cancer and other associated pathologies. On the other hand, low rates of *H. pylori* infection recurrence could constitute a public health benchmark for the control of infection (19). Based on the previous, the objective of this study was to determine the recurrence of *H. pylori* infection and the frequency of *H. pylori* virulent strains isolated in adult patients treated in a specialized hospital who had undergone empirical standard triple therapy one year after eradication.
Material and methods.

A longitudinal prospective quasi-experimental study was performed with a pre and post-test in one single group. The study was approved by the Commission for Research and Ethics at our hospital. The study did not violate authorship, plagiarism, conflict of interests and informed consent criteria.

The study included a population of consecutive adult patients attending the endoscopy service for an upper digestive videoendoscopy due to various reasons (uninvestigated dyspepsia, gastrointestinal bleeding, anemia and peptic ulcer, among others) and in whom *H. pylori* infection had been confirmed. None of the patients in the study were under treatment with proton-pump inhibitors (PPIs), sucralfate or antibiotics prior to *H. pylori* infection diagnosis by means of an endoscopy. All patients were treated with empirical standard triple therapy (40 mg omeprazole, 500 gr clarithromycin and 1 gr amoxicillin twice daily for two weeks). This is the current first-line regimen in Mexico, the bacteria elimination rates are higher than 90% and 80% as calculated on an intention to treat basis. This is according to the recommendations of the III Mexican Consensus on *H. pylori* of the Mexican Gastroenterology Association (20). The study was performed from January 2014 to December 2016 at the Gastroenterology Service of the Regional ISSSTE Hospital in Culiacán, Sinaloa in the North East of Mexico. Prior to eradication treatment, a histological study was performed and different types of *H. pylori* strains were isolated and identified (*cagA* and *vacA* genes with subtypes s1, s2, m1 and m2) in gastric samples. Eradication of the bacteria was confirmed via the Carbon 14 breath test and infection was monitored during one year. This is the predetermined time-period for conducting a breath test with Carbon 14. When a positive result was obtained, a new upper digestive videoendoscopy was performed in order to obtain a gastric sample and isolate and identify *H. pylori* strains. The inclusion criteria for patients were as follows: male and female gender; 18 to 80 years of age; the eradication of *H. pylori* infection confirmed via a Carbon 14 breath test six weeks after the eradication treatment; the isolation and identification of the type of *H. pylori* strain prior to eradication treatment and signed informed consent. Patients with previous recurrences of *H. pylori* infection were
excluded as well as patients who had not been monitored via gastroenterology appointments for one year. Patients were also excluded due to data collection errors and when the isolation and identification of the type of *H. pylori* strain failed in patients with a positive Carbon 14 breath test after one year of monitoring.

**Definition of the variables**

The eradication of *H. pylori* infection was defined based on a negative result from the Carbon 14 breath test six weeks after eradication treatment. The fact that the patient had not received PPI treatment, H2 blockers, sucralfate or antibiotics was verified. The recurrence of *H. pylori* infection was defined as a relapse of *H. pylori* infection caused by the same or a different strain (combination of the cagA and vacA genes with the s1, s2, m1 and m2 subtypes) of the bacteria after eradication using standard triple therapy. Re-infection with *H. pylori* was defined as an infection caused by the bacteria of a different genotype (combination of the cagA and vacA genes with the s1, s2, m1 and m2 subtypes) one year after treatment with standard triple therapy. Recrudescence of *H. pylori* infection was defined using a genotype identical to the strains isolated one year after eradication using standard triple therapy (cagA and vacA genes with the s1, s2, m1, and m2 subtypes) (14). The histological findings obtained from the gastric mucosa were defined according to the classification of the updated Sydney System (21).

**Sample**

The estimated sample size in order to detect the difference between the hypothetical and alternative proportions of 0.615 (Delta) was 126 patients. The proportion of 0.0385 for the null hypothesis was taken from a review of a study conducted in Peru (19) and the alternative value of 0.10 was used. The one-tailed Z test statistic was used. The significance level of the test was set at 0.05 with a power of 0.80. A proportion of 20% patient loss was expected. Non-probabilistic sampling was used both for convenience and for the number of consecutive patients.

**Data collection**
The data was collected via a primary source from the direct observation of the stomach (gastric fundus, body and antrum) from two antral gastric samples and two body samples by means of upper digestive videoendoscopy. Data was also collected from the findings of the histological study, cultures and Polymerase Chain Reaction (PCR) of the cagA and vacA genes from the gastric mucosa samples.

**Equipment and biological samples.**

*The upper digestive endoscopy technique and gastric biopsies*

The upper digestive endoscopy was performed under intravenous sedation using an Olympus EG 29-90I videoendoscope by applying an oropharyngeal xylocaine spray in the left lateral decubitus position and the placement of the mouthpiece. The macroscopic characteristics of the stomach were recorded. Four biopsies (two from the antrum and two from the body) were taken using FB 25K-1 series biopsy forceps. Two endoscopy specialists evaluated the videoendoscopies and the endoscopic findings were defined according to the updated Sydney System (21).

*Identification of the histological findings and H. pylori infection and strains.*

**Histological study.** The gastric mucosa samples (two from the antrum and two from the body) were processed using a habitual paraffin technique and histological sections were colored with Hematoxylin-Eosin and Giemsa stain. Complementary staining was performed using toluidine blue with a sensitivity and specificity of 96% and 99% respectively (20). The results were evaluated by two pathologists.

**Carbon 14 breath test.** This was performed in fasting patients who had not taken PPIs, H2 blockers, sucralfate and antibiotics in the last 30 days. In order to measure urease activity, patients ingested a urea capsule marked with 1uCi of Carbon 14 for the detection of the marked carbon ten minutes later, via the analysis of the expired air with 20 ml of water. Values lower than 50 Disintegrations Per Minute (DPM) were considered as negative for *H. pylori* infection, while those between 50 and 199 DPM were considered indeterminate and scores greater than 200 DPM were considered as positive (19). Even though the Carbon 14 breath test
contains radioactive material, the radiation received by the patient is at an acceptably low level (0.03 - 0.3 mSv/MBq). This has not been tested sufficiently in either children or pregnant women, therefore the test was not performed in females who could have been pregnant.

Isolation and Identification of *H. pylori* strains.

*Bacterial culture.* Two gastric samples of antral biopsies from each patient were kept in a sterile saline solution (0.9%) at 4 °C and processed for culture within two hours. The biopsies were inoculated onto the surface of Colombia chocolate agar plates enriched with Dent supplement (Oxoid, England) containing vancomycin (5.0 mg), trimethoprim (2.5 mg), cefsulodin (2.5 mg), amphotericin B (2.5 mg) and 1% of fetal calf serum (Gibco, USA). The biopsies were incubated in a microaerophilic atmosphere using a gas generation system that produces 5% of O2 and 14% of CO2 (CampyGen gas packs, Oxoid, Hampshire, England) at 37 °C for 3 to 5 days. The primary *H. pylori* cultures were conserved at -80 °C in brain heart liquid infusion medium (BHI) with 20% of glycerol. The isolated *H. pylori* cultures were identified according to the morphology, Gram strain results and a positive reaction to oxidase, catalase and urease (22).

*Preparation of the genomic DNA of *H. pylori.* Genomic DNA from *H. pylori* cultures was isolated using the Promega Genomic DNA Purification Kit (Madison, Wisconsin) according to the manufacturers’ instructions.

*Molecular detection of *H. pylori.* The identification of the *H. pylori* strains was performed by PCR using a Bio-Rad T100 thermocycler (Bio-Rad Laboratories, Hercules, California). The sequences and running conditions are shown in Table I (23, 24, 25, 26, and 27). When *H. pylori* was identified via the 16S gene, the vacA and cagA virulence genes were also detected using DNA extracted from the ATCC 26695 reference strain of *H. pylori* as a positive control. The PCR reaction was performed in a final volume of 25 μl with the following components: 50 mM of KCl; 20 mM of Tris HCl pH 8.4; 2.5 mM of MgCl2; 0.2 mM of each deoxynucleotide triphosphate; 1 pm/μl of each primer (Table I); 1.25 U of Taq polymerase (InvitrogenTM, USA) and approximately 90 ng/μl of genomic DNA. The PCR
amplification program was specific for each gene analyzed (Table I) and PCR products were viewed via UV using a digital imaging system (Fotodyne, Hartland, Wi) on agarose gels at 2%.

Statistical design. The data was analyzed using the SPSS v 16 software package (SPSS, Inc., Chicago IL, USA). Average and standard deviation values were used as quantitative variables and absolute frequencies and percentages were used as categorical variables. The student T test was used to compare averages and the Fisher’s exact test was used to compare percentages. Statistical significance was set at 0.05.

Results

The H. pylori infection was eradicated in 142 of the 171 patients treated (83 %). Four patients were excluded from the study and a further 9 were eliminated, therefore a total of 128 patients were analyzed (Fig. 1). The average age of the patients was 54.8 years (DE13.8), 51 years (39.8%) for males and 77 years (60.2%) for females. Twenty-nine (22.6%) patients were referred from Primary Care units and 99 (77.4%) patients came from clinical specialties.

The indications for performing an upper digestive endoscopy were uninvestigated dyspepsia in 76 (59.4%) patients, dyspepsia caused by the consumption of nonsteroidal anti-inflammatory drugs in 23 (18%), upper gastrointestinal bleeding in 14 (10.9%), iron-deficiency anemia in 9 (7%), dysphagia in 4 (3.1%) and peptic ulcer in 2 (1.5%) patients. The most common histological finding was non-atrophic chronic gastritis in 114 (89.1%) patients and intestinal metaplasia was identified in 22 (17.2%) patients (Table II).

The annual recurrence rate of H. pylori infection was 12 (9.3%) patients. Annual reinfection was identified in 9 (7%) patients, while annual recrudescence was identified in 3 (2.3 %) patients (Fig. 1). The average age of patients with and without recurrence of H. pylori infection was 60.5 years (DE 9.3) and 54.2 years (DE 14.1), respectively (p = 0.13). With regard to gender, 8/97 (8.2%) women and
4/31 (12.9%) men had a recurrence of *H. pylori* infection (p= 0.323).

The recrudescence rate of *H. pylori* infection in the *cagA* genotype was 1/30 (3.3%) patients, 2/112 (1.8%) for the *vacA* genotype, 1/15 (6.6%) for the s1/m2 genotype and 1/18 (5.5%) patients for the s2/m2 genotype. The signal sequence for Type s1 was identified in 1/72 (1.4 %) patients, 1/31 (3.2%) patients for Type s2 and 2/33 patients (6 %) for the mid-region of Type m2. The rate of *H. pylori* re-infection due to the *cagA* genotype was 3/30 (10%) patients, 6/112 (5.3%) patients for the *vacA* genotypes, 3/18 (16.6%) patients for the s2/m2 genotype, 1/11 (9%) patients for the s1/NT genotype and 2/9 (22.2%) patients for the NT/m1 genotype. The signal sequence for Type s1 was identified in 1/72 (1.4%) patients, the signal sequence for Type s2 was identified in 3/31 (9.7%) patients and the signal sequence was not typed in 2/9 (22.2%) patients. The signal sequence was identified for the mid-region of the Type m1 genotype in 2/68 (2.9%) patients for the mid-region of the Type m2 genotype in 3/33 (9%) patients and the signal sequence for the mid-region was not typed in 1/101 (0.9%) patients (Table III).

No significant difference were found between the frequency of *H. pylori* infection recurrence and the presence of the single or combined genotype (p> 0.05) (Table IV).

Discussion.

The objective of the successful treatment of *H. pylori* infection is eradication. This benefits gastroduodenal disease patients due to lower rates of ulcer recurrence and gastrointestinal bleeding and thus changes the natural history of peptic disease. Published data suggests that *H. pylori* infection eradication treatment could contribute to reducing gastric cancer incidence (12, 28) by modifying the progression of gastric mucosa lesions, for example via the regression of intestinal metaplasia (29). However, despite eradication treatment, *H. pylori* infection can recur. This is of importance as efforts to improve the prognosis of peptic disease and the incidence of gastric cancer could be unsuccessful.
Recrudescence and re-infection by *H. pylori* occur in different contexts, bacteria recrudescence occurs in patients that do not adhere to the eradication treatment or due to a low efficacy of the antibiotic therapy. *H. pylori* re-infection is related to both the high prevalence of infection in the population and environments with a greater risk of transmission. Therefore, recrudescence is a clinical problem that results from treatment failure. Re-infection is considered as a preventive medicine problem and must be treated differently.

An annual recurrence of *H. pylori* infection was found in 12 (9.3%) patients and an annual *H. pylori* re-infection in 9 (7 %) patients, while the annual recrudescence of *H. pylori* infection was identified in 3 (2.3 %) patients. Five different types of *H. pylori* strains were identified according to the combination of the *H. pylori* genes studied. Two types of strains (with the cagA, ovacA ands2/m2 genes) were isolated in both re-infection and recrudescence, suggesting that this type of strain should receive special attention. With regard to re-infection, four different types of *H. pylori* strains were identified with the cagA, vacAs1, vacA s2/m2 and vacA m1 gene combinations. With regard to recrudescence, three different types of *H. pylori* strains were identified with the gene combinations cagA, vacA s1/m2 and vacA s2/m2.

Previous studies on *H. pylori* infection recurrence have obtained different results, perhaps related to the diverse regions and prevalence of *H. pylori* in the different populations (Table V). The study by Gómez Rodríguez BJ and cols. (18) in Spain found a 6.9% rate of recurrence of *H. pylori* infection, which is lower than that found in this study. A prevalence rate of *H. pylori* infection of 60.3% had been previously recorded in Spain (30). The study by Takes S and cols. (31) in Japan found an annual recurrence rate of *H. pylori* infection of 0.8% and the study by Zhou LY and cols. (32) in China found an annual recurrence rate of *H. pylori* infection of 1.75%. The results from the studies in Japan (31) and China (32) were different to those found in this study. The recurrence levels of *H. pylori* infection were low, even though these are developed countries with a lower prevalence of *H. pylori* infection than those found in Mexico. Japan and China have a population prevalence for *H. pylori* infection of 27.5% (33) and 31.9% (34) respectively. The
study by Kim SY and col (35) in Korea found an annual recurrence of *H. pylori* infection of 9.3%, which is similar to the rate observed in this study. Even though Korea is a developed country, there is a high prevalence of *H. pylori* infection of 54.4% (36).

Studies performed in developing countries in Latin America such as the Morgan DR and cols. (37) study in Chile and Colombia found an annual recurrence of *H. pylori* infection of 13.6% and 18.1% respectively. The Sivapalasingam S and cols. (38) study in Bolivia identified a *H. pylori* recurrence rate of 12%. These results are different to those described in this study as recurrence rates were higher in Latin American countries, possibly due to the high prevalence of *H. pylori* infection of 78%, 83.1% and 80% in Chile, Colombia and Bolivia respectively (39,4, 38). The abovementioned studies do not mention whether the recurrence was due to re-infection or recrudescence and only the study by Takes S and cols. (31) in Japan found an annual re-infection rate of 0.2% and an annual recrudescence rate of 0.6%.

One of the limitations of this study is the difficulty in the identification some of the strains from gastric samples. These difficulties begin with the transport and inoculation of the gastric biopsy on the chocolate agar plates for culture. *H. pylori* is vulnerable to desiccation, contact with oxygen and environmental temperature. Biopsies must be stored in saline solution for a period of no more than 4 hours (40) which also affects the isolation of bacteria. Occasionally, the strains cannot be typed due to the variations of the signal sequence and the mid-region in various geographical areas (41), which may explain why the majority of the studies mentioned previously did not determine whether the recurrence was due to *H. pylori* recrudescence or re-infection. The Carbon 13 breath test was not used in this study due to a lack of equipment availability. However, the Carbon 14 breath test has a high detection rate for the recurrence of *H. pylori* infection with a sensitivity of 96.6% and a specificity of 100% (42). Therefore, this did not affect the findings described here. Furthermore, the Kappa index score of correlation between the Carbon 14 breath test and the histological study was 0.56. This could be because the histological study evaluates the presence of *H. pylori* in the gastric
biopsies and the Carbon 14 breath test evaluates the complete gastric mucosa (43). It would have been interesting to compare the recurrence rate of *H. pylori* infection with different first and second-line eradication therapies. No association was found between the recurrence of *H. pylori* infection and other variables such as smoking and breath test levels, which would have provided significant evidence for this research. This prospective study identified recurrence due to *H. pylori* recrudescence or re-infection using culture based techniques and *H. pylori* strains were isolated and identified via PCR. Furthermore, this study also considered that the results could infer a population-type with similar characteristics.

With regard to public health, these results may contribute to reducing the population prevalence of *H. pylori* infection, promoting treatment adherence and the availability of effective therapies for eradication. These factors could also reduce *H. pylori* infection recurrence.

In conclusion, the recurrence of infection in this study in Mexico was higher than that that recorded in developed countries with a low prevalence of *H. pylori* and lower than that recorded in developing countries with a higher prevalence of *H. pylori*. Two types of *H. pylori* strains with cagA, ovacA and s2/m2 genes were isolated in both re-infection and recrudescence.

Acknowledgements. We would like to thank the staff of the endoscopy service at the Regional ISSSTE Hospital, Culiacán and the Program for the Strengthening of Research Projects (PROFAPI/UAS 2014) at the Autonomous University of Sinaloa.

References


17. Parsonnet J. What is the Helicobacter pylori global re-infection rate? Can J Gastroenterol 2003; 17 Suppl B:46B-48B.


<table>
<thead>
<tr>
<th>Gene</th>
<th>Amplified region</th>
<th>Primer</th>
<th>Size of product</th>
<th>Conditions</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>16S</td>
<td>Hypervariable region</td>
<td>GGCCTTATCAACAGAATGGC</td>
<td></td>
<td>95°C/30s, 60°C/30s and 72°C/30s for 30 cycles</td>
<td>(23)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CTCAGTTCGGATTGTAGGCTGC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vacA</td>
<td>s1</td>
<td>ATGGAAATACAACAAAAACAC</td>
<td>259</td>
<td>95°C/60s, 52°C/60s and 72°C/60s for 35 cycles</td>
<td>(24)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CTGCTTGATGCGCAAAAC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>s2</td>
<td>ATGGAAATACAACAAAAACAC</td>
<td>286</td>
<td>95°C/60s, 52°C/60s and 72°C/60s for 35 cycles</td>
<td>(24)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CTGCTTGATGCGCAAAAC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>m1</td>
<td>CAATCTGTCATCAACTGAG</td>
<td>570</td>
<td>95°C/60s, 52°C/60s and 72°C/60s for 35 cycles</td>
<td>(25)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GCGTCTAAATAATCCAGG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>m2</td>
<td>CAATCTGTCATCAACTGAG</td>
<td>645</td>
<td>95°C/60s, 52°C/60s and 72°C/60s for 35 cycles</td>
<td>(25)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GCGTCTAAATAATCCAGG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cagA</td>
<td>Hydrophobic region</td>
<td>GGAATTGTCTGATAAATTG</td>
<td>615</td>
<td>95°C/50s, 50°C/160s and 72°C/160s for 35 cycles</td>
<td>(26)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CCATTATGTTATGTTATG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Region for internal</td>
<td>GGAACCTAGCGGTAATG</td>
<td>450</td>
<td>95°C/50s, 50°C/160s and 72°C/160s for 35 cycles</td>
<td>(27)</td>
</tr>
<tr>
<td></td>
<td>duplications</td>
<td>ATCTTTGAGCTTTGTCTATG</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table II. Histological findings from the gastric mucosa in subjects with a H. pylori infection treated with empirical standard triple therapy in the Regional ISSSTE Hospital, Culiacán, Sinaloa, Mexico, from January 2014 to December 2016

<table>
<thead>
<tr>
<th>Types of gastritis *</th>
<th>f(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute gastritis</td>
<td>10 (7.8%)</td>
</tr>
<tr>
<td>Chronic non-atrophic gastritis</td>
<td>114 (89.1%)</td>
</tr>
<tr>
<td>Chronic atrophic gastritis</td>
<td>4 (3.1%)</td>
</tr>
<tr>
<td>Metaplasia *</td>
<td>22 (17.2%)</td>
</tr>
<tr>
<td>Type I Metaplasia</td>
<td>17 (77.2%)</td>
</tr>
<tr>
<td>Type II Metaplasia</td>
<td>5 (22.7%)</td>
</tr>
</tbody>
</table>

* Updated Sydney System

Table III. Rate of recurrence of H. pylori infection with regard to genotype one year after eradication with empirical standard triple therapy in patients from the regional ISSSTE hospital, Culiacán, Sinaloa Mexico, from January 2014 to December 2016.

<table>
<thead>
<tr>
<th>vacA</th>
<th>Recrudescence</th>
<th>Re-infection</th>
<th>Recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>yes</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>s1/m1</td>
<td>f</td>
<td>%</td>
<td>f</td>
</tr>
<tr>
<td>s1/m2</td>
<td>15</td>
<td>13.9</td>
<td>1</td>
</tr>
<tr>
<td>s2/m1</td>
<td>13</td>
<td>11.6</td>
<td>0</td>
</tr>
<tr>
<td>s2/m2</td>
<td>18</td>
<td>16</td>
<td>1</td>
</tr>
<tr>
<td>s1/NT</td>
<td>11</td>
<td>9.8</td>
<td>0</td>
</tr>
<tr>
<td>NT*/m1</td>
<td>9</td>
<td>8</td>
<td>0</td>
</tr>
</tbody>
</table>

Accepted Article
### cagA

<table>
<thead>
<tr>
<th></th>
<th>30</th>
<th>23.4</th>
<th>1</th>
<th>3.3</th>
<th>29</th>
<th>96.7</th>
<th>3</th>
<th>10</th>
<th>27</th>
<th>90</th>
<th>4</th>
<th>13.3</th>
<th>26</th>
<th>86.7</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Non-typed

Table IV. Rate of recurrence of *H. pylori* infection with regard to a unique and combined genotype one year after eradication using empirical standard triple therapy in patients from the regional ISSSTE hospital, Culiacán, Sinaloa, Mexico, from January 2014 to December 2016.

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Recrudescence</th>
<th>Re-infection</th>
<th>Recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>vacA</td>
<td>f</td>
<td>%</td>
<td>f</td>
</tr>
<tr>
<td>vacA</td>
<td>98</td>
<td>76.5</td>
<td>2</td>
</tr>
<tr>
<td>cagA</td>
<td>16</td>
<td>12.5</td>
<td>1</td>
</tr>
<tr>
<td>Combination vacA y cagA</td>
<td>14</td>
<td>10.9</td>
<td>0</td>
</tr>
</tbody>
</table>

* Fisher’s exact test. Statistical significance 0.05
* Comparison of unique genotypes vacA and cagA
* Comparison of unique and combined genotypes.

Table V. Recurrence of *H. pylori* infection one year after eradication treatment in various countries

<table>
<thead>
<tr>
<th>Country</th>
<th>Year</th>
<th>n</th>
<th>Annual recurrence</th>
<th>Prevalence of <em>H. pylori</em> in the population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gómez Rodríguez BJ (18)</td>
<td>Spain</td>
<td>2004</td>
<td>208</td>
<td>14 (6.7%)</td>
</tr>
<tr>
<td>Take S (31)</td>
<td>Japan</td>
<td>2012</td>
<td>1609</td>
<td>13 (0.8%)</td>
</tr>
<tr>
<td>Zhou LY (32)</td>
<td>China</td>
<td>2017</td>
<td>743</td>
<td>13 (1.75%)</td>
</tr>
<tr>
<td>Kim SY (35)</td>
<td>Korea</td>
<td>2014</td>
<td>1283</td>
<td>119 (9.3%)</td>
</tr>
<tr>
<td>Morgan DR (37)</td>
<td>Chile</td>
<td>2013</td>
<td>154</td>
<td>21 (13.6%)</td>
</tr>
<tr>
<td>Sivapalasingam S (38)</td>
<td>Bolivia</td>
<td>2014</td>
<td>1065</td>
<td>128 (12%)</td>
</tr>
<tr>
<td>Morgan DR (37)</td>
<td>Colombia</td>
<td>2013</td>
<td>166</td>
<td>30 (18.1%)</td>
</tr>
<tr>
<td>This study</td>
<td>Mexico</td>
<td>2017</td>
<td>128</td>
<td>12 (9.3%)</td>
</tr>
</tbody>
</table>
Patients evaluated for inclusion into the study who had undergone eradication treatment with standard triple therapy after *H. pylori* infection.

n=142

Patients included with eradication of *H. pylori* infection using standard triple therapy.

n=137

n=128 patients studied.

Annual recurrence of *H. pylori* infection
12/128 (9.3%)

Re-infection
9/128 (7%)

Recrudescence
3/128 (2.3%)

5 patients excluded due to a history of recurrence of *H. pylori* infection.

9 Patients eliminated due to a lack of one year of follow-up monitoring appointments at the gastroenterology service.

Fig. 1 Flowchart. Samples and patients analyzed for inclusion, patients included, excluded and eliminated from the study of the re-infection and recrudescence of *H. pylori* infection in patients treated with standard triple therapy in the regional ISSSTE hospital, Culiacán, Sinaloa, Mexico, from January 2014 to December 2016.